Literature DB >> 9724846

A gene therapy approach to treatment of autoimmune disease.

C M Seroogy1, C G Fathman.   

Abstract

New insights into the underlying mechanisms for the development of autoimmune diseases in humans and various animal models continue to increase with our understanding of factors that drive polarization of T helper (Th) responses and tolerance. This information has led to the development of new treatment strategies, including oral tolerance clinical trails and the use of altered peptide ligands in animal models. These approaches have shown some promise and provided additional insight into the disease processes. The use of gene therapy in many disease states continues to increase. We are starting to see the application of gene therapy in chronic diseases in humans. Gene therapy has been used in several animal models of autoimmune disease with promising preliminary results. In this article, an overview will be provided for the use of gene therapy in autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9724846     DOI: 10.1007/BF02786510

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  49 in total

1.  Responses to ragweed-pollen nasal challenge before and after immunotherapy.

Authors:  P S Creticos; D G Marsh; D Proud; A Kagey-Sobotka; N F Adkinson; L Friedhoff; R M Naclerio; L M Lichtenstein; P S Norman
Journal:  J Allergy Clin Immunol       Date:  1989-08       Impact factor: 10.793

2.  Adeno-associated virus type 2-mediated transfer of ecotropic retrovirus receptor cDNA allows ecotropic retroviral transduction of established and primary human cells.

Authors:  K Qing; T Bachelot; P Mukherjee; X S Wang; L Peng; M C Yoder; P Leboulch; A Srivastava
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

3.  Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein.

Authors:  S Brocke; K Gijbels; M Allegretta; I Ferber; C Piercy; T Blankenstein; R Martin; U Utz; N Karin; D Mitchell; T Veromaa; A Waisman; A Gaur; P Conlon; N Ling; P J Fairchild; D C Wraith; A O'Garra; C G Fathman; L Steinman
Journal:  Nature       Date:  1996-01-25       Impact factor: 49.962

4.  Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses.

Authors:  V A Varney; Q A Hamid; M Gaga; S Ying; M Jacobson; A J Frew; A B Kay; S R Durham
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

Review 5.  Acquisition of lymphokine-producing phenotype by CD4+ T cells.

Authors:  R A Seder; W E Paul
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

6.  Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: a phase I clinical trial.

Authors:  G Bellon; L Michel-Calemard; D Thouvenot; V Jagneaux; F Poitevin; C Malcus; N Accart; M P Layani; M Aymard; H Bernon; J Bienvenu; M Courtney; G Döring; B Gilly; R Gilly; D Lamy; H Levrey; Y Morel; C Paulin; F Perraud; L Rodillon; C Sené; S So; F Touraine-Moulin; A Pavirani
Journal:  Hum Gene Ther       Date:  1997-01-01       Impact factor: 5.695

7.  Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice.

Authors:  L Mori; S Iselin; G De Libero; W Lesslauer
Journal:  J Immunol       Date:  1996-10-01       Impact factor: 5.422

8.  T lymphocytes in collagen II-induced arthritis in mice. Characterization of arthritogenic collagen II-specific T-cell lines and clones.

Authors:  R Holmdahl; L Klareskog; K Rubin; E Larsson; H Wigzell
Journal:  Scand J Immunol       Date:  1985-09       Impact factor: 3.487

9.  Effects of oral administration of type II collagen on rheumatoid arthritis.

Authors:  D E Trentham; R A Dynesius-Trentham; E J Orav; D Combitchi; C Lorenzo; K L Sewell; D A Hafler; H L Weiner
Journal:  Science       Date:  1993-09-24       Impact factor: 47.728

10.  Autoimmunity to type II collagen an experimental model of arthritis.

Authors:  D E Trentham; A S Townes; A H Kang
Journal:  J Exp Med       Date:  1977-09-01       Impact factor: 14.307

View more
  1 in total

1.  Transduced viral IL-10 is exocytosed from lacrimal acinar secretory vesicles in a myosin-dependent manner in response to carbachol.

Authors:  Jiansong Xie; Ronald R Marchelletta; Padmaja B Thomas; Damon T Jacobs; Francie A Yarber; Richard E Cheney; Sarah F Hamm-Alvarez; Melvin D Trousdale
Journal:  Exp Eye Res       Date:  2008-11-13       Impact factor: 3.467

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.